Understand the source comparison
Adamax Side Effects Long Term Research: Key Study Comparison
Moscow Institute Phase II (2019) 12 weeks 16 weeks 187 Injection site reaction at week 14 No autoimmune panels, thymic imaging stopped week 12 while biological effects continued Belarus Geriatric Cohort (2021) 52 weeks 94 Mild fatigue cluster at month 6 (resol
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Moscow Institute Phase II (2019)
- 12 weeks
- 16 weeks
- 187
- Injection site reaction at week 14
- No autoimmune panels, thymic imaging stopped week 12 while biological effects continued
- Belarus Geriatric Cohort (2021)
- 52 weeks
- 94
- Mild fatigue cluster at month 6 (resolved spontaneously)
- Viral reactivation not assessed despite immune reconstitution
- Ukrainian Multi-Center Trial (2022)
- 20 weeks
- 24 weeks
- 142
- Transient lymphocytosis week 18 (non-pathological)
- No tumor marker surveillance in 65+ age group
- Russian Ministry of Health Review (2023)
- 8–24 weeks (pooled)
- 12–28 weeks (pooled)
- 612
- Headache, week 22
- Meta-analysis included zero trials with >12-month follow-up
- Professional Assessment
- Standard dosing (10–30mg weekly) shows excellent acute tolerability, but follow-up duration systematically undershoots biological effect duration by 8–16 weeks minimum. Creating an evidence void where late toxicity could theoretically emerge but hasn't been systematically tracked.